<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03854149</url>
  </required_header>
  <id_info>
    <org_study_id>PROTECT_AR_trial_01102018_v1.0</org_study_id>
    <nct_id>NCT03854149</nct_id>
  </id_info>
  <brief_title>A Prospective Study on the Safety and Efficacy of Apixaban for the PReventiOn of ThromboEmbolism in Adults With Congenital HearΤ Disease and Atrial ARrhythmias</brief_title>
  <acronym>PROTECT_AR</acronym>
  <official_title>A Prospective Study on the Safety and Efficacy of Apixaban for the PReventiOn of ThromboEmbolism in Adults With Congenital HearΤ Disease and Atrial ARrhythmias</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AHEPA University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Onassis Cardiac Surgery Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Attikon Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>MITERA Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AHEPA University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of apixaban for the
      prevention of thromboembolism in adult patients with congenital heart disease (CHD) and
      non-valvular atrial arrhythmias (AA)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adult patients with congenital heart disease (ACHD) represent a rapidly growing population
      due to the progress of surgical techniques and optimal medical management. Non-valvular
      atrial arrhythmias (AA) carries a significant burden for long-term morbidity and potentially
      mortality in ACHD patients. AA occur three times more frequently in ACHD compared to the
      general population. When complicating ACHD, AA convey a twofold increase in the risk for
      stroke, contributing to an up to 100-fold higher prevalence of stroke in the ACHD population
      compared to age-matched healthy controls. At present, the European Society of Cardiology
      (ESC) Guidelines suggest oral anticoagulation (OAC) in all adult patients with AA and
      intracardiac repair, cyanosis, Fontan palliation, or systemic right ventricle. In the
      remaining ACHD patients with AA, OAC is suggested if CHA2DS2-Vasc (congestive heart failure,
      hypertension, age ≥75 years, diabetes mellitus, stroke/transient ischemic attack, vascular
      disease, age 65 to 74 years, sex category) score is ≥1 (Class of recommendation IIa, level of
      evidence C).

      Non-vitamin K oral anticoagulants (NOACs) are increasingly preferred over vitamin-K
      antagonists (VKAs) in most clinical scenarios due to improved safety (with regard to
      intracranial and other major bleeding) and efficacy (prevention of embolic stroke or systemic
      embolism) along with the convenience they offer for patients and physicians (fixed dose, no
      food and drug interactions, no INR monitoring). On the other hand, scarce data is available
      on the use of NOAC in ACHD.

      In order to address this gap in evidence, we propose a prospective multicenter single arm,
      observational cohort trial, which will provide data on the efficacy and safety of apixaban
      used for the prevention of thromboembolism in ACHD patients with AA.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>24 Months</target_duration>
  <primary_outcome>
    <measure>Stroke, systemic or pulmonary arterial thromboembolism and intracardiac thrombosis.</measure>
    <time_frame>24 months</time_frame>
    <description>The composite endpoint of all-cause stroke, systemic and pulmonary embolism and intracardiac thrombosis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major bleeding</measure>
    <time_frame>24 months</time_frame>
    <description>Defined as clinically overt bleeding that is associated with:
A fall in hemoglobin of 2 g/dL or more
A transfusion of ≥2 units of packed red blood cells or whole blood
Bleeding in a critical site: intracranial, intraspinal, intraocular, pericardial, intraarticular, intramuscular with compartment syndrome, retroperitoneal
Death (fatal bleeding)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Trantient ischemic attack</measure>
    <time_frame>24 months</time_frame>
    <description>Defined as new neurologic symptoms or deficit lasting less than 24 hours with no new infarction on neuroimaging (if available).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>24 months</time_frame>
    <description>Defined as the detection of a significant rise/fall of Troponin in association with symptoms of ischemia, ECG changes, proof of ischemia on imaging or intracoronary thrombus at angiography. [Fourth definition of myocardial infarction; European Society of Cardiology (ESC) 2018]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death from cardiovascular causes</measure>
    <time_frame>24 months</time_frame>
    <description>Cardiovascular deaths were classified as deaths due to: ischemic stroke, hemorrhagic stroke, systemic or pulmonary embolism, other cardiovascular (i.e., myocardial infarction, sudden death, heart failure) and unobserved deaths.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Τhe composite of major and clinically relevant nonmajor bleeding</measure>
    <time_frame>24 months</time_frame>
    <description>Clinically relevant nonmajor bleeding bleeding=bleeding that is clinically overt, that satisfies none of the additional criteria required for the event to be adjudicated as a major bleeding event, that led to either hospital admission for bleeding, physician-guided medical or surgical treatment for bleeding, or a change in antithrombotic therapy.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>General quality of life</measure>
    <time_frame>24 months</time_frame>
    <description>Assessed with questionnaire SF-36</description>
  </other_outcome>
  <other_outcome>
    <measure>Apixaban persistence</measure>
    <time_frame>24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Apixaban adherence</measure>
    <time_frame>24 months</time_frame>
    <description>Assessed by reviewing electronic pharmacy prescription data</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Congenital Heart Disease</condition>
  <condition>Atrial Arrhythmia</condition>
  <condition>Thromboembolism</condition>
  <condition>Anticoagulants Causing Adverse Effects in Therapeutic Use</condition>
  <arm_group>
    <arm_group_label>Adults with CHD &amp; non-valvular atrial arrhythmias</arm_group_label>
    <description>Adults with congenital heart disease and non-valvular atrial arrhythmias (atrial fibrillation, atrial flutter or intra-atrial re-entrant tachycardia)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban</intervention_name>
    <description>Apixaban 5mg or an adjusted dose of 2.5mg twice daily use</description>
    <arm_group_label>Adults with CHD &amp; non-valvular atrial arrhythmias</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with Congenital Heart Disease and Non-Valvular Atrial Arrhythmias who are
        routinely treated with apixaban (i.e., new or ongoing users) for stroke prevention at any
        health-care level in Greece
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patients aged ≥18 years.

          2. Presence of congenital heart disease (intracardiac repair, cyanosis, Fontan
             palliation, or systemic right ventricle or other congenital heart disease).

          3. Non-Valvular Atrial Arrhythmia (including at least one electrocardiographically
             documented episode).

          4. Signed written informed consent by the patient for participation in the study and
             agreement to comply with the medication and the follow-up schedule.

        Exclusion Criteria:

          1. moderate-to-severe mitral stenosis or mechanical valves

          2. patient unwilling or unable to complete follow-up procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Georgios Giannakoulas, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>AHEPA University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Georgios Giannakoulas, MD, PhD</last_name>
    <phone>2310994830</phone>
    <phone_ext>0030</phone_ext>
    <email>ggiannakoulas@auth.gr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Attikon University Hospital</name>
      <address>
        <city>Athens</city>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandra Frogoudaki, MD</last_name>
      <email>afrogou@otenet.gr</email>
    </contact>
    <investigator>
      <last_name>Alexandra Frogoudaki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sotiria Liori, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mitera Children's Hospital</name>
      <address>
        <city>Athens</city>
        <zip>15123</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aphrodite Tzifa, MD</last_name>
      <email>atzifa@mitera.gr</email>
    </contact>
    <investigator>
      <last_name>Aphrodite Tzifa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Onassis Cardiac Surgery Centre</name>
      <address>
        <city>Athens</city>
        <zip>17674</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sotiria Apostolopoulou, MD</last_name>
      <email>riapos@hol.gr</email>
    </contact>
    <investigator>
      <last_name>Sotiria Apostolopoulou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olga Ntzouvara, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AHEPA University Hospital</name>
      <address>
        <city>Thessaloníki</city>
        <zip>54636</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georgios Giannakoulas, MD, PhD</last_name>
      <phone>2310994830</phone>
      <phone_ext>0030</phone_ext>
      <email>ggiannakoulas@auth.gr</email>
    </contact>
    <investigator>
      <last_name>Georgios Giannakoulas, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charalambos Karvounis, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Georgios Rampidis, MD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ioannis Doundoulakis, MD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anastasios Kartas, MD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Despoina Ntiloudi, MD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <link>
    <url>https://www.hcs.gr/challenge.aspx</url>
    <description>CHALLENGE Registry</description>
  </link>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>February 23, 2019</study_first_submitted>
  <study_first_submitted_qc>February 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2019</study_first_posted>
  <last_update_submitted>November 26, 2019</last_update_submitted>
  <last_update_submitted_qc>November 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>AHEPA University Hospital</investigator_affiliation>
    <investigator_full_name>George Giannakoulas</investigator_full_name>
    <investigator_title>Assistant Professor - MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Congenital Heart Disease</keyword>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Thromboembolism</keyword>
  <keyword>NOAC</keyword>
  <keyword>Apixaban</keyword>
  <keyword>Atrial arrhythmias</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Arrhythmias, Cardiac</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apixaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

